Back to search
Triple-negative Breast Cancer (TNBC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Triple-negative Breast Cancer (TNBC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Triple-negative Breast Cancer (TNBC) trials you may qualify forThe phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieve…
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with a…
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from…
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which ty…
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the b…
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatmen…
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥…
The goal of this clinical trial is to identify cellular and molecular determinants of response to neoadjuvant immunochemotherapy in women aged 18 or older with…
This is a single-arm and single site phase II trial combination of chemotherapy and pembrolizumab with LBP MO-03 in 50 trial participants with early triple nega…